AR043110A1 - LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE - Google Patents

LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE

Info

Publication number
AR043110A1
AR043110A1 ARP040100347A ARP040100347A AR043110A1 AR 043110 A1 AR043110 A1 AR 043110A1 AR P040100347 A ARP040100347 A AR P040100347A AR P040100347 A ARP040100347 A AR P040100347A AR 043110 A1 AR043110 A1 AR 043110A1
Authority
AR
Argentina
Prior art keywords
salt
triethanolamine
useful
low molecular
therapeutic
Prior art date
Application number
ARP040100347A
Other languages
Spanish (es)
Original Assignee
Syntex Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Sa filed Critical Syntex Sa
Priority to ARP040100347A priority Critical patent/AR043110A1/en
Priority to US11/024,082 priority patent/US20050234015A1/en
Priority to JP2004379644A priority patent/JP4607575B2/en
Priority to CA2491398A priority patent/CA2491398C/en
Priority to EP05250081A priority patent/EP1561760B1/en
Priority to DE602005011189T priority patent/DE602005011189D1/en
Priority to AT05250081T priority patent/ATE415424T1/en
Priority to CNB2005100091529A priority patent/CN100564397C/en
Publication of AR043110A1 publication Critical patent/AR043110A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sal de heparina de bajo peso molecular con trietanolamina útil como agente terapéutico-antitrombótico de administración tópica, que comprende al menos 60% de su masa total con un peso molecular inferior a 8000 Da y un peso molecular promedio comprendido entre 4000 y 6000 Da, presentando además dicha sal un contenido de azufre orgánico de entre 6,1 y 7,5 % en peso (teórico 6,8 % en peso) y un contenido de trietanolamina de entre 42,6 y 52,1 % en peso (teórico 47,4 % en peso). Se describen además procedimientos para preparar dichas sales, proceso para la eliminación de la higroscopicidad de la sal de heparina, composiciones farmacéuticas para uso tópico en terapia antitrombótica y usos en dichas terapias.Low molecular weight heparin salt with triethanolamine useful as a topical administration therapeutic-antithrombotic agent, comprising at least 60% of its total mass with a molecular weight less than 8000 Da and an average molecular weight between 4000 and 6000 Da, presenting said salt also has an organic sulfur content of between 6.1 and 7.5% by weight (theoretical 6.8% by weight) and a triethanolamine content of between 42.6 and 52.1% by weight (theoretical 47, 4% by weight). Methods for preparing said salts, process for the removal of the hygroscopicity of the heparin salt, pharmaceutical compositions for topical use in antithrombotic therapy and uses in said therapies are also described.

ARP040100347A 2004-02-04 2004-02-04 LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE AR043110A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ARP040100347A AR043110A1 (en) 2004-02-04 2004-02-04 LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE
US11/024,082 US20050234015A1 (en) 2004-02-04 2004-12-28 Low molecular weight heparin salt with triethanolamine useful as therapeutic-antitrombotic agent of local delivery, procedures for preparing them, process for elimination of hygroscopicity of heparin salt, pharmaceutical compositions for local use in antithrombotic therapy and uses therein
JP2004379644A JP4607575B2 (en) 2004-02-04 2004-12-28 Low molecular weight heparin salts with triethanolamine useful as antithrombotic agents for the treatment of local delivery, methods for their preparation, processes for removing the hygroscopic properties of heparin salts, pharmaceuticals for local use in antithrombotic therapy Composition and use in the same
CA2491398A CA2491398C (en) 2004-02-04 2005-01-04 Processes for preparing triethanolamine salts of low molecular weight heparin and their use in topical creams for antithrombotic therapy
EP05250081A EP1561760B1 (en) 2004-02-04 2005-01-10 Low molecular weight heparin salt with triethanolamine
DE602005011189T DE602005011189D1 (en) 2004-02-04 2005-01-10 Salt of low molecular weight heparin with triethanolamine
AT05250081T ATE415424T1 (en) 2004-02-04 2005-01-10 LOW MOLECULAR WEIGHT HEPARIN SALT WITH TRIETHANOLAMINE
CNB2005100091529A CN100564397C (en) 2004-02-04 2005-02-04 Be used as its method for making of LMWH-TEA and the purposes of the antithrombotic treatment agent of topical

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP040100347A AR043110A1 (en) 2004-02-04 2004-02-04 LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE

Publications (1)

Publication Number Publication Date
AR043110A1 true AR043110A1 (en) 2005-07-20

Family

ID=34658432

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100347A AR043110A1 (en) 2004-02-04 2004-02-04 LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE

Country Status (8)

Country Link
US (1) US20050234015A1 (en)
EP (1) EP1561760B1 (en)
JP (1) JP4607575B2 (en)
CN (1) CN100564397C (en)
AR (1) AR043110A1 (en)
AT (1) ATE415424T1 (en)
CA (1) CA2491398C (en)
DE (1) DE602005011189D1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101735336B (en) * 2009-11-06 2012-07-18 深圳海王药业有限公司 Oligomeric fucosylated glycosaminoglycan and preparation method thereof
CN101724086B (en) 2009-11-25 2012-09-26 深圳海王药业有限公司 Oligomerization pineapple ginseng glycosaminoglycan and preparation method thereof
CA2811186C (en) * 2010-09-14 2018-12-04 Michio Muguruma High purity heparin and production method therefor
CN102746421B (en) * 2012-05-23 2014-03-12 杭州龙扬生物科技有限公司 Impurity removing technology of crude heparin sodium
RU2539380C1 (en) * 2014-01-14 2015-01-20 Александр Ливиевич Ураков Bruise bleacher
CN104188902B (en) * 2014-08-25 2017-03-29 深圳市天道医药有限公司 A kind of production technology of high stability Dalteparin Sodium Injection
CN104479047B (en) * 2014-12-20 2016-08-17 山东绅联生物科技有限公司 A kind of extracting method of middle product heparin sodium
RU2573382C1 (en) * 2015-01-16 2016-01-20 Александр Ливиевич Ураков Agent for intradermal bruise whitening
RU2639283C1 (en) * 2016-12-12 2017-12-20 Общество с ограниченной ответственностью "Институт термологии" Method for whitening of bruise under eye
RU2639485C1 (en) * 2017-01-23 2017-12-21 Общество с ограниченной ответственностью "Институт термологии" Means for intravital skin whitening near blue eyes
CN111019014A (en) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 Preparation process of nadroparin calcium
CN114773530B (en) * 2022-03-29 2023-05-12 河南驼人医疗器械研究院有限公司 Polymer emulsion with anticoagulation function and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3020220A1 (en) * 1980-05-28 1981-12-03 Theodor Prof. Dr. 4400 Münster Eckert Heparin and heparinoid salts with organic bases - e.g. di:ethylamine, tri:ethanolamine, tri:ethylamine or buphenine
DE3331009A1 (en) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen METHOD FOR INCREASING THE ENTERAL RESORBABILITY OF HEPARIN OR. HEPARINOIDS AND THE SO AVAILABLE HEPARIN OR HEPARINOID PREPARATION
FR2584728B1 (en) * 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
AR243204A1 (en) * 1986-11-21 1993-07-30 Ajorca Sa A method for the chemical depolymerisation of polysaccharides.
DE3744119A1 (en) * 1987-12-24 1989-07-06 Basf Ag USE OF POLYSULFATED HEPARINES
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
DE10141106A1 (en) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Use of heparinoid derivatives for the treatment and diagnosis of heparinoid-treatable diseases
EP1542704A1 (en) * 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients

Also Published As

Publication number Publication date
CA2491398C (en) 2011-04-12
ATE415424T1 (en) 2008-12-15
JP2005220347A (en) 2005-08-18
DE602005011189D1 (en) 2009-01-08
CN100564397C (en) 2009-12-02
EP1561760B1 (en) 2008-11-26
CA2491398A1 (en) 2005-08-04
CN1651470A (en) 2005-08-10
US20050234015A1 (en) 2005-10-20
JP4607575B2 (en) 2011-01-05
EP1561760A3 (en) 2007-03-28
EP1561760A2 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
AR043110A1 (en) LOW MOLECULAR HEPARINE SALT WITH USEFUL TRIETHANOLAMINE AS A THERAPEUTIC-ANTITROMBOTIC AGENT OF TOPICAL ADMINISTRATION, PROCEDURES TO PREPARE SALES, PROCESS FOR THE ELIMINATION OF HYPROSCOPICITY SALT IN PHAROSERIC ACIACIACEUTIC USE IN TOP THERAPY PAPER USE
BRPI0615292A8 (en) compositions and methods for preparing poorly soluble water drugs with increased stability
BRPI0508540A (en) compound, pharmaceutical composition, and use of a compound
CY1115825T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LEVETIRAKETAM AND THEIR PREPARATION PROCEDURE
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
PL1933809T3 (en) Compositions for nasal delivery
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
CL2010000606A1 (en) Use of erythropoietin derivatives in the preparation of a useful medicine to protect, maintain, improve or recover the viability of cells that respond to erythropoietin under abnormal conditions that affect the associated cells, tissues or organs; Erythropoietin derivatives and composition comprising them (divisional of application 3188-2001).
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
DK1331927T3 (en) Topical composition containing at least one vitamin D or vitamin D analogue and at least one dietary chosteroid
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
BR112018013979A2 (en) gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
RS51185B (en) Compositions for vaginal use
BRPI0504445A (en) thrombin composition and process for its preparation
BR0109672A (en) Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal
YU2703A (en) Clear aqueous anesthetic composition
BR112017026287A2 (en) hydroxypropyl beta-cyclodextrin compositions and methods
PT2576524T (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
BRPI0707488B8 (en) method for producing an epoprostenol composition, pharmaceutical composition and stable solution
BR112015017246A2 (en) pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
AR048672A1 (en) DISINTEGRATION TABLETS THAT INCLUDE LICARBAZEPINA
BR0312365A (en) Autologous human autologous progenitor mother cell culture medium, methods for the preparation thereof and a composition of human autologous progenitor mother cell and for obtaining autologous human progenitor muscle mother cells, use of an autologous human autologous progenitor culture medium human autologous progenitor mother cells, procedure for obtaining human autologous muscle progenitor mother cells and therapeutic procedure for autologous cell cardiomyoplasty, composition enriched with human autologous muscle progenitor mother cells and pharmaceutical composition
BR112015010256A2 (en) means for cultivating, preserving and administering regenerative cells
WO2016196950A1 (en) Olivamine-induced improvement in endothelial cells viability and function
BR112022003046A8 (en) Il-15 conjugate, its method of preparation and its uses, as well as pharmaceutical composition and in vitro method of expanding one or more of the t cell populations

Legal Events

Date Code Title Description
FG Grant, registration